The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.
Biogen, Inc. underscored its commitment to Alzheimer’s disease while announcing the discontinuation of three clinical-stage development programs as new CEO Christopher Viehbacher continues to piece together a business strategy that will return the company to steady growth beginning in 2025. Executives updated investors on Biogen’s ongoing business review during its first quarter sales and earnings call on 25 April.
“What we’re really trying to do is redesign the company,”
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An ‘historic economic prosperity deal’ does not include the sector.
